The Senate Special Committee on Aging will hold a hearing on January 29, 2026, to address transparency issues related to the country of origin labeling for generic drugs and active pharmaceutical ingredients sold in the United States. The session, titled “Truth in Labeling: Americans Deserve to Know Where Their Drugs Come From,” is led by Committee Chairman Rick Scott and Ranking Member Kirsten Gillibrand.
According to the committee, many prescription drugs are manufactured in countries such as China or India, often with limited oversight. This leaves patients and healthcare providers uncertain about the origins of their medications. The hearing aims to examine potential risks this situation poses for patients and the pharmaceutical supply chain.
Committee members and expert witnesses will discuss possible legislative solutions, including requirements for clear labeling of drug origins. These measures are intended to improve transparency and encourage domestic pharmaceutical manufacturing.
“This hearing follows a bipartisan investigative report from Chairman Scott and Ranking Member Gillibrand aimed at strengthening oversight of U.S. pharmaceutical supply chains and exposing America’s dangerous overreliance on foreign-made generic drugs,” according to the committee. The statement also notes that both senators have sent more than a dozen letters to federal agencies and industry leaders seeking information to ensure greater transparency and accountability.
Witnesses scheduled for the hearing include Dr. John Gray from Ohio State University’s Fisher College of Business; Dr. Michael Ganio, Senior Director of Pharmacy Practice & Quality at ASHP; Dr. Stephen W. Schondelmeyer from the University of Minnesota College of Pharmacy; and Stephen Colvill, Deputy Director of Research at Duke-Margolis Institute for Health Policy.
The hearing will take place at 9:30 a.m. ET in room SD-608 of the Dirksen Senate Office Building, with a live stream available online.
